Ischemic protection and myofibrillar cardiomyopathy: dose-dependent effects of in vivo deltaPKC inhibition.
To delineate the in vivo cardiac functions requiring normal delta protein kinase C (PKC) activity, we pursued loss-of-function through transgenic expression of a deltaPKC-specific translocation inhibitor protein fragment, deltaV1, in mouse hearts. Initial results using the mouse alpha-myosin heavy chain (alphaMHC) promoter resulted in a lethal heart failure phenotype. Viable deltaV1 mice were therefore obtained using novel attenuated mutant alphaMHC promoters lacking one or the other thyroid response element (TRE-1 and -2). In transgenic mouse hearts, deltaV1 decorated cytoskeletal elements and inhibited ischemia-induced deltaPKC translocation. At high levels, deltaV1 expression was uniformly lethal, with depressed cardiac contractile function, increased expression of fetal cardiac genes, and formation of intracardiomyocyte protein aggregates. Ultrastructural and immunoconfocal analyses of these aggregates revealed focal cytoskeletal disruptions and localized concentrations of desmin and alphaB-crystallin. In individual cardiomyocytes, cytoskeletal abnormalities correlated with impaired contractile function. Whereas desmin and alphaB-crystallin protein were increased approximately 4-fold in deltaV1 hearts, combined overexpression of these proteins at these levels was not sufficient to cause any detectable cardiac pathology. At low levels, deltaV1 expression conferred striking resistance to postischemic dysfunction, with no measurable effects on basal cardiac structure, function, or gene expression. Intermediate expression of deltaV1 conferred modest basal contractile depression with less ischemic protection, associated with abnormal cardiac gene expression, and a histological picture of infrequent cardiomyocyte cytoskeletal deformities. These results validate an approach of deltaPKC inhibition to protect against myocardial ischemia, but indicate that there is a threshold level of deltaPKC activation that is necessary to maintain normal cardiomyocyte cytoskeletal integrity.
Hahn
Harvey S
HS
Department of Internal Medicine, Division of Cardiology, University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0542, USA.
Yussman
Martin G
MG
Toyokawa
Tsuyoshi
T
Marreez
Yehia
Y
Barrett
Thomas J
TJ
Hilty
K Chad
KC
Osinska
Hanna
H
Robbins
Jeffrey
J
Dorn
Gerald W
GW
D000818:Animals; D009202:Cardiomyopathies / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D002316:Cardiotonic Agents; D002478:Cells, Cultured; D003459:Crystallins / Q000378:metabolism; D003599:Cytoskeleton / Q000648:ultrastructure; D003893:Desmin / Q000378:metabolism; D004791:Enzyme Inhibitors; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D009200:Myocardial Contraction; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000517:prevention & control; D009206:Myocardium / Q000201:enzymology* / Q000378:metabolism / Q000648:ultrastructure; D018995:Myosin Heavy Chains / Q000235:genetics; D009924:Organ Culture Techniques; D010641:Phenotype; D011401:Promoter Regions, Genetic; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D051745:Protein Kinase C-delta; D016019:Survival Analysis
D002316:Cardiotonic Agents; D003459:Crystallins; D003893:Desmin; D004791:Enzyme Inhibitors; D007527:Isoenzymes; C497259:Prkcd protein, mouse; D011493:Protein Kinase C; D051745:Protein Kinase C-delta; D018995:Myosin Heavy Chains